The Relationship of the Factor V Leiden Mutation and Pregnancy Outcomes for Mother and Fetus

Dizon‐Townson, Donna; Miller, Connie H.; Sibai, Baha M.; Spong, Catherine Y.; Thom, Elizabeth; Wendel, George D.; Wenstrom, Katharine D.; Samuels, Philip; Cotroneo, Margaret; Moawad, Atef H.; Sorokin, Yoram; Meis, Paul J.; Miodovnik, Menachem; OʼSullivan, Mary J.; Conway, Deborah L.; Wapner, Ronald J.; Gabbe, Steven G.

doi:10.1097/01.aog.0000173986.32528.ca

Cited by 238 publications

(117 citation statements)

References 25 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Our results were in accordance with a study that had reported that frequencies of factor V Leiden were not found to be significantly different in a group of patients with at least one unexplained second trimester abortion, at least one intra-uterine fetal death, severe PEC or severe IUGR compared with patients who had uneventful pregnancies [12]. However, some findings from our study do contradict other reports in the literature, in which associations between thrombophilia mutations and a variety of adverse pregnancy outcomes, such as IUGR and PEC, have been established [13,14,15,16,17]. …”

Section: Discussioncontrasting

confidence: 83%

The Status of Thrombophilic Defects and Non-O Blood Group as Risk Factors for Gestational Vascular Complications among Tunisian Women

Klai¹,

Fekih-Mrissa²,

Rachdi

et al. 2010

Acta Haematol

View full text Add to dashboard Cite

Aims: Our objectives were to assess inherited thrombophilia and non-O blood group for the risk of gestational vascular complications among the Tunisian population. Methods: This study comprised 203 test subjects with adverse pregnancy outcomes including recurrent pregnancy loss, intra-uterine growth retardation, pre-eclampsia and placental abruption. Each subgroup was matched with 100 controls and analyzed separately. All patients were evaluated for factor V Leiden, factor II G20210A mutations and for non-O blood group. Protein S, protein C and antithrombin levels were determined and deficiencies noted. Results: The factor V Leiden mutation, non-O blood group and protein C deficiency had the highest incidences among patients both as a whole and in the 4 subgroups. The factor II G20210A mutation, protein S and antithrombin deficiencies were not statistically significant risk factors. Conclusion: Our results provide evidence for a significant association between the factor V mutation and placental abruption. Furthermore, we found that this and the non-O blood group independently increased the risk for intra-uterine growth retardation in our population.

show abstract

Section: Discussioncontrasting

confidence: 83%

The Status of Thrombophilic Defects and Non-O Blood Group as Risk Factors for Gestational Vascular Complications among Tunisian Women

Klai¹,

Fekih-Mrissa²,

Rachdi

et al. 2010

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…There have been suggestions that thrombophilias are related to increased risk of obstetric complications in case-control studies. In large cohorts a prevalent thrombophilia like factor V Leiden has not been significantly related to obstetric complications or prematurity [13,21,22]. To the best of our knowledge women with prior VTE have not been related to premature delivery in large series.…”

Section: Discussionmentioning

confidence: 86%

The effect of low molecular weight heparin (dalteparin) on duration and initiation of labour

Isma

Svensson

Lindblad

et al. 2009

J Thromb Thrombolysis

View full text Add to dashboard Cite

It has recently been reported that women treated with low molecular weight heparin (LMWH) during pregnancy had 3 h shorter duration of delivery. The aim of the present study was to evaluate whether LMWH (dalteparin) affects labour. From January 1996 to December 2005, 217 consecutive pregnancies, out of 34 216 newborn (prevalence 0.6%) that were given thromboprophylaxis with dalteparin (usually 5,000 IU once daily). These 217 consecutive pregnancies were compared to an unselected control group (n = 1,499) of gravidae. Main outcome was time in first and second stage of labour and gestational age at delivery. Among nulliparous women, there were significantly fewer women with prolonged first stage of labour as compared to controls (4.1% vs. 8.5%, P = 0.047). In addition, the duration of first stage of labour was 1 h shorter among those treated with LMWH (5.2 vs. 6.2 h, P = 0.06). There were no such differences among parous women. The risk of prematurity, profuse blood loss, and postpartum anaemia was almost doubled among those treated with LMWH (11.5% vs. 5.9%, P = 0.002, 10.6% vs. 5.9%, P < 0.001, and 12.9% vs. 8.7%, P = 0.048, respectively). Treatment with a prophylactic dose of LMWH (dalteparin) during pregnancy was related to fewer women with prolonged first stage of labour, but also to an increased risk of prematurity and blood loss complications.

show abstract

“…Rodger et al [8 ]in a review of 16,959 women, in whom an FV Leiden prevalence of 4.7% was observed, reported an OR of pregnancy loss of 1.32. In 2 prospective, multicenter studies, no correlation was found between the presence of the FV Leiden and/or FIIG20210A mutations and miscarriage rate [25,26]. Finally, similar outcomes were reported in a European prospective study [27].…”

Section: Discussionmentioning

confidence: 64%

“…For example, Kupfermic et al [22] recorded a higher frequency of thrombophilia factors (FV Leiden, FIIG20210A and MTHFR C677T mutations) in 110 women with pregnancy failure than in those who had had normal pregnancies (52 vs. 17%, respectively; p < 0.001). However, several studies reveal discordant results regarding the role of congenital thrombophilia factors, namely FV Leiden and FIIG20210A in pregnancy loss [7,8,23,24,25,26,27]. A recent meta-analysis published by Bradley et al [7 ]reported that women with recurrent pregnancy loss carrying the FV Leiden mutation were more likely to have a subsequent loss than those noncarriers.…”

Section: Discussionmentioning

confidence: 99%

Maternal Thrombophilia and Adverse Pregnancy Outcome: A Case-Control Study

Mazzucconi

Sanctis²,

Alfó

et al. 2014

Acta Haematol

View full text Add to dashboard Cite

Objective: To assess the risk of adverse pregnancy outcomes in patients with acquired and/or congenital thrombophilia factors. Patients and Methods: A cohort of 130 women with a history of pregnancy loss and no successful gestation were investigated for the presence of congenital and acquired thrombophilia factors, and then compared with a control group of 130 healthy women who had had at least one successful gestation and no pregnancy loss, and were screened for congenital and acquired thrombophilia factors. Results: Acquired and congenital thrombophilia factors were found in 30 (23%) patients and in 14 (10.8%) controls (p < 0.015). The presence of ≥1 congenital thrombophilia factor was associated with pregnancy loss with an odds ratio of 2.46 (p = 0.040). Moreover, women who had had >1 early fetal loss had a 2.85-fold risk of being carriers of congenital thrombophilia factors, compared to the controls. Conclusion: Our study showed the increased risk of miscarriage in patients with congenital thrombophilia factors and >1 early fetal loss. © 2014 S. Karger AG, Basel

show abstract

The Relationship of the Factor V Leiden Mutation and Pregnancy Outcomes for Mother and Fetus

Abstract: II-2.

Cited by 238 publications

References 25 publications

The Status of Thrombophilic Defects and Non-O Blood Group as Risk Factors for Gestational Vascular Complications among Tunisian Women

The Status of Thrombophilic Defects and Non-O Blood Group as Risk Factors for Gestational Vascular Complications among Tunisian Women

The effect of low molecular weight heparin (dalteparin) on duration and initiation of labour

Maternal Thrombophilia and Adverse Pregnancy Outcome: A Case-Control Study

Contact Info

Product

Resources

About